Chang GC - Search Results

1

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.

Scagliotti G, Moro-Sibilot D, Kollmeier J, Favaretto A, Cho EK, Grosch H, Kimmich M, Girard N, Tsai CM, Hsia TC, Brighenti M, Schumann C, Wang XA, Wijayawardana SR, Gruver AM, Wallin J, Mansouri K, Wacheck V, Chang GC. Scagliotti G, et al. Among authors: chang gc. J Thorac Oncol. 2020 Jan;15(1):80-90. doi: 10.1016/j.jtho.2019.10.003. Epub 2019 Oct 14. J Thorac Oncol. 2020. PMID: 31622732 Free article. Clinical Trial.

2

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.

Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP, Su WP, Gow CH, Hsu C, Chang GC, Yang PC. Yang CH, et al. Among authors: chang gc. Cancer. 2006 Oct 15;107(8):1873-82. doi: 10.1002/cncr.22220. Cancer. 2006. PMID: 16989002 Free article.

3

Revisit of 1997 TNM staging system--survival analysis of 1112 lung cancer patients in Taiwan.

Perng RP, Chen CY, Chang GC, Hsia TC, Hsu NY, Tsai YH, Tsai CM, Yang CH, Chen YM, Yu CJ, Lee JJ, Hsu HS, Yu CT, Kao EL, Chiu CH. Perng RP, et al. Among authors: chang gc. Jpn J Clin Oncol. 2007 Jan;37(1):9-15. doi: 10.1093/jjco/hyl119. Epub 2006 Dec 1. Jpn J Clin Oncol. 2007. PMID: 17142253

4

Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.

Chang GC, Tsai CM, Chen KC, Yu CJ, Shih JY, Yang TY, Lin CP, Hsu JY, Chiu CH, Perng RP, Yang PC, Yang CH. Chang GC, et al. J Thorac Oncol. 2006 Jul;1(6):520-5. J Thorac Oncol. 2006. PMID: 17409911 Free article.

5

High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.

Perng RP, Yang CH, Chen YM, Chang GC, Lin MC, Hsieh RK, Chu NM, Lai RS, Su WC, Tsao CJ, Hsia TC, Chen HC, Chen CH, Huang MS, Wang JL, Ho ML, Chung CY, Yu CJ, Chang WC, Kuo HP, Yu CT, Lin ZZ, Kao WY. Perng RP, et al. Among authors: chang gc, chang wc. Lung Cancer. 2008 Oct;62(1):78-84. doi: 10.1016/j.lungcan.2008.02.023. Epub 2008 Apr 18. Lung Cancer. 2008. PMID: 18423781 Clinical Trial.

6

Patient awareness of prognosis, patient-family caregiver congruence on the preferred place of death, and caregiving burden of families contribute to the quality of life for terminally ill cancer patients in Taiwan.

Tang ST, Liu TW, Tsai CM, Wang CH, Chang GC, Liu LN. Tang ST, et al. Among authors: chang gc. Psychooncology. 2008 Dec;17(12):1202-9. doi: 10.1002/pon.1343. Psychooncology. 2008. PMID: 18521969

7

Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns.

Hsu KH, Chen KC, Yang TY, Yeh YC, Chou TY, Chen HY, Tsai CR, Chen CY, Hsu CP, Hsia JY, Chuang CY, Tsai YH, Chen KY, Huang MS, Su WC, Chen YM, Hsiung CA, Chang GC, Chen CJ, Yang PC. Hsu KH, et al. Among authors: chang gc. J Thorac Oncol. 2011 Jun;6(6):1066-72. doi: 10.1097/JTO.0b013e31821667b0. J Thorac Oncol. 2011. PMID: 21512404 Free article.

8

Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.

Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL. Tsai CM, et al. Among authors: chang gc. J Thorac Oncol. 2011 Jun;6(6):1092-7. doi: 10.1097/JTO.0b013e318216687d. J Thorac Oncol. 2011. PMID: 21512405 Free article. Clinical Trial.

9

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.

Mok TS, Hsia TC, Tsai CM, Tsang K, Chang GC, Chang JW, Sirisinha T, Sriuranpong V, Thongprasert S, Chua DT, Moore N, Manegold C. Mok TS, et al. Among authors: chang jw, chang gc. Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:4-12. doi: 10.1111/j.1743-7563.2011.01397.x. Asia Pac J Clin Oncol. 2011. PMID: 21585703 Clinical Trial.

10

Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.

Yuan S, Yu SL, Chen HY, Hsu YC, Su KY, Chen HW, Chen CY, Yu CJ, Shih JY, Chang YL, Cheng CL, Hsu CP, Hsia JY, Lin CY, Wu G, Liu CH, Wang CD, Yang KC, Chen YW, Lai YL, Hsu CC, Lin TC, Yang TY, Chen KC, Hsu KH, Chen JJ, Chang GC, Li KC, Yang PC. Yuan S, et al. Among authors: chang yl, chang gc. J Clin Oncol. 2011 Sep 1;29(25):3435-42. doi: 10.1200/JCO.2011.35.3979. Epub 2011 Aug 1. J Clin Oncol. 2011. PMID: 21810691

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters